Entropy Neurodynamics (ASX:ENP) EBIT: A$-4.72 Mil (TTM As of Dec. 2025)


What is Entropy Neurodynamics EBIT?

Entropy Neurodynamics ASX:ENP -3.23% EBIT is A$-4.72 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Entropy Neurodynamics's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was A$-3.42 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.72 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Entropy Neurodynamics's annualized ROC % for the quarter that ended in Dec. 2025 was -259.38%. Entropy Neurodynamics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -649.12%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Entropy Neurodynamics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -10.93%.

Entropy Neurodynamics  (ASX:ENP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Entropy Neurodynamics's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-6.928 * ( 1 - 0% )/( (3.046 + 2.296)/ 2 )
=-6.928/2.671
=-259.38 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6.663 - 0.591 - ( 3.026 - max(0, 0.699 - 6.351+3.026))
=3.046

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9.075 - 0.353 - ( 6.426 - max(0, 1.127 - 8.773+6.426))
=2.296

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Entropy Neurodynamics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-6.832/( ( (0.115 + max(-0.136, 0)) + (0.104 + max(1.886, 0)) )/ 2 )
=-6.832/( ( 0.115 + 1.99 )/ 2 )
=-6.832/1.0525
=-649.12 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.563) - (0.591 + 0 + 0.108)
=-0.136

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.95 + 0 + 0.397) - (0.353 + 0 + 0.108)
=1.886

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Entropy Neurodynamics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-4.72/43.195
=-10.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entropy Neurodynamics EBIT Related Terms

Entropy Neurodynamics EBIT Historical Data

* Premium members only.

The historical data trend for Entropy Neurodynamics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entropy Neurodynamics EBIT Chart

Entropy Neurodynamics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun25
EBIT
Get a 7-Day Free Trial -8.01 -12.67 -10.00 -6.80 -5.33

Entropy Neurodynamics Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -1.93 -4.02 -1.30 -3.42

ASX:ENP vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Entropy Neurodynamics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entropy Neurodynamics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Entropy Neurodynamics's EV-to-EBIT falls into.


Entropy Neurodynamics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-4.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of A$-4.72 Mil mean?
Entropy Neurodynamics (ASX:ENP) has a EBIT of A$-4.72 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Entropy Neurodynamics.
Is Entropy Neurodynamics' EBIT too high?
Entropy Neurodynamics' current EBIT is A$-4.72 Mil.
How does Entropy Neurodynamics' EBIT compare to VRTX and REGN?
Entropy Neurodynamics' EBIT of A$-4.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Entropy Neurodynamics. Entropy Neurodynamics's current EBIT is A$-4.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (ASX:ENP) is currently considered Fairly Valued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.03 — trading right at its estimated fair value. The current EBIT is A$-4.72 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Entropy Neurodynamics (ASX:ENP), the current EBIT is A$-4.72 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entropy Neurodynamics Business Description

Other Exchanges TYPTF:USA
Address 117 Camberwell Road,, Hawthorn East, Suite 1.01, Camberwell, Melbourne, VIC, AUS, 3123
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.